Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of limited fresh-freezing capacity on patients’ access to emerging cancer (a) testing and (b) treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) fresh-freezing, (b) snap-freezing and (c) flash frozen capacity for brain cancer tissue samples across NHS trusts in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Kim Johnson (Labour - Liverpool Riverside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the funding required to ensure equitable access to tissue-freezing services for cancer patients across England; and whether his Department is taking steps to reduce regional disparities.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues. Individual pathology services maintain their own standard operating procedures (SOPs) for fresh, or snap-freezing, of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support National Health Service trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Neil Hudson (Conservative - Epping Forest)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve access to routine tissue freezing for brain cancer patients in a) Epping Forest and b) England for even access to advanced treatments, diagnostics and research.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
No recent assessment has been made on the adequacy, extent, or capacity of procedures for freezing brain cancer and general cancer tissue samples across National Health Service trusts in Epping Forest or England.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Richard Holden (Conservative - Basildon and Billericay)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has identified general dental practices participating in locally commissioned schemes to provide prioritised oral healthcare for patients undergoing cancer treatment.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is working to ensure that patients who have a diagnosis of cancer receive timely, safe, and effective dental care.
NHS England has produced guidelines which aim to ensure that patients across England with a diagnosis of cancer, including oral cancer, have equitable access to oral healthcare. This could include oral health assessments, prevention, rehabilitation, and reconstruction in primary, either National Health Service or independent, community, secondary, or tertiary care settings. This would be provided as part of a multi-disciplinary team care plan. Ongoing oral health management for the duration of the cancer therapy would take place. Further information can be found at the following link:
https://www.england.nhs.uk/publication/oral-healthcare-provision-for-cancer-pathways/
The responsibility for commissioning primary care dentistry to meet the needs of the local population is delegated to the integrated care boards (ICBs) across England. In the South West a number of pilot models are being trialled, for example, if a patient does not have 'a usual dental practice’ and has primary dental care requirements, they will be referred to specific general dental practices, referred to as cancer action support practices, based in ICBs where the pathway is running.
Participation in schemes supporting patients undergoing cancer treatment does not create any automatic entitlement to additional contractual or financial support. Any supplementary funding, including through flexible commissioning, is determined locally and subject to commissioner discretion, identified local need, and available resources.
Asked by: Richard Holden (Conservative - Basildon and Billericay)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps NHS England is taking to encourage integrated care boards to commission prioritised oral health pathways for patients undergoing cancer treatment; and whether practices that participate in such schemes are eligible for additional contractual or financial support.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is working to ensure that patients who have a diagnosis of cancer receive timely, safe, and effective dental care.
NHS England has produced guidelines which aim to ensure that patients across England with a diagnosis of cancer, including oral cancer, have equitable access to oral healthcare. This could include oral health assessments, prevention, rehabilitation, and reconstruction in primary, either National Health Service or independent, community, secondary, or tertiary care settings. This would be provided as part of a multi-disciplinary team care plan. Ongoing oral health management for the duration of the cancer therapy would take place. Further information can be found at the following link:
https://www.england.nhs.uk/publication/oral-healthcare-provision-for-cancer-pathways/
The responsibility for commissioning primary care dentistry to meet the needs of the local population is delegated to the integrated care boards (ICBs) across England. In the South West a number of pilot models are being trialled, for example, if a patient does not have 'a usual dental practice’ and has primary dental care requirements, they will be referred to specific general dental practices, referred to as cancer action support practices, based in ICBs where the pathway is running.
Participation in schemes supporting patients undergoing cancer treatment does not create any automatic entitlement to additional contractual or financial support. Any supplementary funding, including through flexible commissioning, is determined locally and subject to commissioner discretion, identified local need, and available resources.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the training provided to GPs on prescribing risk-reducing drugs to women at increased risk of breast cancer.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
General practitioners (GPs) are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This activity should include taking account of new research and developments in guidance, such as that produced by the National Institute for Health and Care Excellence, to ensure that they can continue to provide high quality care to all patients.
We are investing an additional £1.1 billion in GPs, bringing total spend on the GP Contract to £13.4 billion in 2025/26, the biggest increase in over a decade. The 8.9% boost to the GP Contract in 2025/26 is bigger than the 5.8% growth to the National Health Service budget as a whole, demonstrating our commitment to shifting resources to the community.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a national register to capture and integrate the data of all women at increased risk of breast cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Disease Registration Service (NDRS) in NHS England provides England’s national resource for data and analytics on cancer, rare diseases, and congenital conditions.
The NDRS already serves as a national register for women at very high risk of breast cancer. NDRS curates and quality assures the collected data to ensure sufficient accuracy and completeness. The NDRS works closely with the very high risk National Breast Screening Programme to ensure safe and robust identification of women at very high risk of cancer. The integration of this data within the wider NDRS cancer data infrastructure maximises the use of this data which helps with service planning, evaluation, and improvement, and reduces the fragmentation and siloing that would occur with standalone registers.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the accuracy of data collected on all women at increased risk of breast cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Disease Registration Service (NDRS) in NHS England provides England’s national resource for data and analytics on cancer, rare diseases, and congenital conditions.
The NDRS already serves as a national register for women at very high risk of breast cancer. NDRS curates and quality assures the collected data to ensure sufficient accuracy and completeness. The NDRS works closely with the very high risk National Breast Screening Programme to ensure safe and robust identification of women at very high risk of cancer. The integration of this data within the wider NDRS cancer data infrastructure maximises the use of this data which helps with service planning, evaluation, and improvement, and reduces the fragmentation and siloing that would occur with standalone registers.
Asked by: Kevin Hollinrake (Conservative - Thirsk and Malton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NICE's draft guidance on brexucabtagene autoleucel on (a) the Life Sciences Strategy and (b) outcomes for patients with rare cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government remains committed to the ambitions set out in the Life Sciences Sector Plan, which set out an ambition that by 2030, we will be one of the top three fastest places in Europe for patient access to medicines. We will achieve this by reducing friction in the system to optimise access and uptake of new medicines so the most clinically and cost-effective can reach patients faster.
The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it should be recommended for routine National Health Service use following a period of managed access through the Cancer Drugs Fund. NICE’s draft guidance, published in December 2025, does not recommend it as a clinically and cost-effective use of NHS resource, although NICE has not yet published final guidance. The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.